Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial
Authors' conclusion
In this post hoc analysis, in participants with obesity or overweight, tirzepatide was associated with meaningfully reduced SUA levels, regardless of participants' baseline BMI or SUA levels, and appeared to be so primarily via weight reduction.
Study context
- Population
- Adults with obesity or overweight (BMI ≥ 30 kg/m² or ≥27 kg/m² and at least 1 weight-related complication)
- Participants
- 2,539 adults
- Comparison
- Tirzepatide 5, 10 or 15 mg vs placebo for 72 weeks
- Primary endpoint
- Change in serum uric acid (SUA)
- Follow-up
- Week 72
Methodological detailspost hoc analysis, placebo-controlled, mediation analysis
- Post hoc analysis
- Placebo-controlled
- Mediation analysis
Primary result
As reported in the abstract
Tirzepatide 5 mg
−0.69
mean · SE 0.04 · mg/dL
Tirzepatide 10 mg
−0.92
mean · SE 0.04 · mg/dL
Tirzepatide 15 mg
−0.95
mean · SE 0.04 · mg/dL
Placebo
−0.18
mean · SE 0.04 · mg/dL
Tirzepatide 5 mg vs Placebo: P < 0.001 · Tirzepatide 10 mg vs Placebo: P < 0.001 · Tirzepatide 15 mg vs Placebo: P < 0.001
Further findings
Serum uric acid (SUA) reduction over time vs placebo by baseline uric acid quartiles and baseline BMI
- SUA reduced significantly vs placebo regardless of baseline uric acid quartiles
- P = 0.610
- SUA reduced significantly vs placebo regardless of baseline BMI values
- P = 0.362
Mediation of SUA reduction by weight reduction
- Proportion of SUA reduction explained by weight reduction
- 72.7%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →